NCT00652847View on ClinicalTrials.gov

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

PHASE4CompletedINTERVENTIONAL

Enrollment

1,140

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Hypercholesterolemia

Interventions

DRUG

ezetimibe

ezetimibe 10 mg/day for a six week course of treatment.

DRUG

statins

patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00652847 - Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED) | Biotech Hunter | Biotech Hunter